John G. Ullman & Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

John G. Ullman & Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.21M	Sell	32,833 -1,567	-5%	-$274K	0.82%	38
2025 Q4	$5.85M	Sell	34,400 -975	-3%	-$149K	0.78%	39
2025 Q3	$4.66M	Sell	35,375 -535	-1%	-$64.2K	0.63%	51
2025 Q2	$3.81M	Sell	35,910 -3,208	-8%	-$348K	0.57%	58
2025 Q1	$4.86M	Sell	39,118 -632	-2%	-$82.4K	0.75%	44
2024 Q4	$4.9M	Sell	39,750 -5,344	-12%	-$630K	0.72%	47
2024 Q3	$5.02M	Sell	45,094 -11,400	-20%	-$1.25M	0.72%	48
2024 Q2	$6.03M	Buy	56,494 +26,344	+87%	+$2.9M	0.92%	33
2024 Q1	$3.63M	Buy	+30,150	New	+$3.69M	0.56%	56

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

John G. Ullman & Associates's JAZZ Position: Q1 2026 in Review

John G. Ullman & Associates reduced its Jazz Pharmaceuticals (JAZZ) stake by 4.6% in Q1 2026, selling an estimated $274K and leaving 32,833 shares worth $6.21M. The position accounts for 0.82% of the portfolio, ranked #38.

John G. Ullman & Associates first reported a position in JAZZ in Q1 2024 and has held it in 9 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

John G. Ullman & Associates held 32,833 shares of Jazz Pharmaceuticals worth $6.21M as of Q1 2026.
John G. Ullman & Associates sold 1,567 Jazz Pharmaceuticals shares in Q1 2026, an estimated $274K.
Jazz Pharmaceuticals made up 0.82% of John G. Ullman & Associates's portfolio in Q1 2026, its #38 holding.
John G. Ullman & Associates first reported a position in Jazz Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on John G. Ullman & Associates's 13F filing for Q1 2026, filed 6 May 2026.